Category Archives: Hormone Refractory Disease

MDV 3100 Clinical Study

Posted on April 24, 2012 by "Coach" Israel Barken M.D.

Question of the week: What’s the latest on the MDV 3100 clinical study?  What is the mode of action of this oral drug?   Video Blog Presentation: Dr. Celestia Higano will talk about the status of the drug and info about … Continue reading →

Posted in Castration Resistant Prostate Cancer, Hormonal Blockade, Hormone Refractory Disease, Metastatic Disease, Treatments for Prostate Cancer | Tagged | Leave a comment

Stromal Targeted Therapy in Bone Metastatic Disease

Posted on March 6, 2012 by "Coach" Israel Barken M.D.

The following question is for the Ask Dr Barken Call In Show on Tuesday, March 6th at 6pm Pacific Time.  Dial 1-877-727-3301 to hear the program. Question of the week:    When should I start treating my bone metastatic disease?   … Continue reading →

Posted in Bone Metastases, Castration Resistant Prostate Cancer, Hormone Refractory Disease, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer | Tagged , , , | Leave a comment

New drug in the pipeline called Cabozantinib (XL184)

Posted on September 13, 2011 by "Coach" Israel Barken M.D.

XL184 is a new drug that is being developed to treat metastatic prostate cancer in the bone. XL184 works by blocking the “angiogenesis,” or the growth of new blood vessels, to the tumor. Dr. Barken reviews briefly information from the … Continue reading →

Posted in Hormone Refractory Disease, Journal Club, Metastatic Disease, Metastatic Prostate Cancer Disease, Treatments for Prostate Cancer | Tagged , | Leave a comment